Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline
Adam Koppel and his team at Bain Capital are carving out the neurosciences pipeline that Pfizer shuttered at the beginning of the year, setting aside …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
